PAL-GHK - Research Grade Peptide

PAL-GHK – Research-Grade Palmitoylated Tripeptide

For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, consumption, clinical use or therapeutic application. It must not be used in any way that contravenes applicable laws or the requirements of the Medicines and Healthcare products Regulatory Agency.

• Research-grade Palmitoyl Tripeptide-1 laboratory material with batch documentation available where supplied
• Defined Gly-His-Lys tripeptide sequence containing an N-terminal palmitoyl modification
• Supplied as measured dry or lyophilised laboratory material in sealed flip-top headspace vials
• Batch identity, chromatographic purity, lipopeptide content and analytical specifications stated in the applicable Certificate of Analysis
• Handled and supplied exclusively as a research-use laboratory material

PAL-GHK, also known as Palmitoyl Tripeptide-1, is a synthetic lipopeptide comprising the tripeptide sequence Gly-His-Lys modified with an N-terminal palmitoyl group. Each vial contains measured laboratory material prepared to support controlled scientific handling, storage and analytical investigation. The stated nominal amount refers to the declared PAL-GHK content of a single vial, subject to the applicable batch documentation. Where dissolution is required, the solvent, concentration, handling procedure and storage conditions stated in the applicable Certificate of Analysis, Safety Data Sheet or validated laboratory method should be followed. We do not provide advice or recommendations concerning dosage, administration or use in humans or animals.

Chemical and Structural Information:

• Product Name: PAL-GHK
• Preferred Substance Name: Palmitoyl Tripeptide-1
• Alternative Names: Pal-GHK; Palmitoyl-GHK tripeptide; Palmitoylglycylhistidyllysine; Palmitoyl oligopeptide; N-palmitoyl-Gly-His-Lys
• Material Classification: Synthetic N-terminally palmitoylated tripeptide and lipopeptide
• Peptide Sequence Length: Three amino-acid residues
• Core Peptide Sequence: Gly-His-Lys
• One-Letter Core Sequence: GHK
• Complete Structural Shorthand: Pal-Gly-His-Lys-OH
• Alternative Structural Shorthand: Pal-GHK-OH
• Systematic Name: N-(1-oxohexadecyl)glycyl-L-histidyl-L-lysine
• N-Terminal Modification: The N-terminal glycine is covalently acylated with a hexadecanoyl or palmitoyl group
• C-Terminal Structure: Free L-lysine carboxylic acid terminus
• Copper Content: None in the defined PAL-GHK molecular structure
• Disulphide-Bond Content: None; the GHK sequence contains no cysteine residues
• CAS Number: 147732-56-7
• PubChem Compound Identifier: CID 10231864
• Unique Ingredient Identifier: RV743D216M
• Molecular Formula: C₃₀H₅₄N₆O₅
• Average Molecular Weight: Approximately 578.79 g/mol
• Calculated Monoisotopic Mass: Approximately 578.4156 Da
• Formula Basis: The molecular formula and molecular weight describe the uncountered PAL-GHK free-acid structure without trifluoroacetate, acetate, residual water, solvents, formulation excipients or other batch-dependent components
• Physical Form: Dry powder or lyophilised laboratory material, as stated in the applicable batch Certificate of Analysis
• Appearance: White to off-white laboratory material, subject to confirmation in the applicable batch Certificate of Analysis
• Product-Identity Clarification: PAL-GHK is the palmitoylated derivative of the GHK tripeptide and is not chemically identical to unmodified GHK
• GHK-Cu Distinction: PAL-GHK is not the copper complex GHK-Cu and the defined molecular formula contains no copper atom
• Mixture Distinction: This listing describes the single Palmitoyl Tripeptide-1 substance and should not be interpreted as an unspecified multi-ingredient lipopeptide blend
• Purity Specification: The applicable chromatographic purity result, analytical method and acceptance criterion are stated in the batch Certificate of Analysis
• Purity Interpretation: Chromatographic purity represents the relative chromatographic composition measured under the stated analytical conditions and should not automatically be interpreted as equivalent to total net PAL-GHK content
• Lipopeptide-Content Specification: Net PAL-GHK content should be distinguished from chromatographic purity and interpreted alongside water, counter-ion, residual-solvent and formulation results
• Sequence Confirmation: The complete Gly-His-Lys sequence should be confirmed using the applicable supplier, synthesis and batch records
• Palmitoylation Confirmation: Product identity should confirm the presence and N-terminal position of the palmitoyl modification using suitable mass-spectrometry or equivalent molecular-identity data
• Terminal-Structure Confirmation: The applicable molecular-identity documentation should confirm the free C-terminal carboxylic acid structure
• Mass-Spectrometry Confirmation: Molecular identity should be supported by analytical mass data consistent with the specified PAL-GHK molecular structure
• Chemical-Form Confirmation: The applicable Certificate of Analysis should identify whether the supplied laboratory material is the uncountered free-acid lipopeptide, a trifluoroacetate form, an acetate form or another counter-ion presentation
• Counter-Ion Specification: Trifluoroacetate, acetate or another counter-ion may affect the total supplied material mass and calculated net PAL-GHK content
• Nominal Amount Basis: The applicable product specification should state whether the declared vial quantity is expressed as net PAL-GHK equivalent or as total supplied salt-form or formulated material
• Water-Content Specification: Residual water may contribute to the total material mass and should be stated or controlled through the applicable batch specification
• Residual-Solvent Specification: Applicable residual solvents arising from peptide synthesis, cleavage, palmitoylation, chromatographic purification and lyophilisation should be stated or controlled through the batch specification
• Related-Impurity Control: Unmodified GHK, incomplete peptide sequences, deletion sequences, incompletely palmitoylated material, free palmitic acid, acylation-related by-products and other synthesis-related or process-related impurities are separate quality attributes
• Aggregation and Physical State: Aggregation, micelle formation and other concentration-dependent physical behaviour are separate quality attributes and are not established by a chromatographic purity percentage alone
• Dissolution Method: The appropriate solvent, co-solvent, concentration and mixing procedure should be selected using the applicable batch documentation and validated laboratory method; a universal solvent instruction should not be applied to every PAL-GHK preparation
• Endotoxin Specification: The applicable bacterial endotoxin or lipopolysaccharide result, analytical method, reporting units, method-suitability controls and acceptance criterion should be stated in the batch Certificate of Analysis
• Sterility Distinction: A bacterial endotoxin or lipopolysaccharide result does not establish sterility. Sterility should only be claimed where supported by an appropriate validated sterility test and controlled filling process
• Analytical Interpretation: Molecular identity, amino-acid sequence, N-terminal palmitoylation, terminal structure, chromatographic purity, net lipopeptide content, aggregation, water content, residual solvents, counter-ion content and bacterial endotoxin results are separate analytical measurements and should be interpreted together

✓ Batch documentation – Completed Certificate of Analysis documentation is provided where supplied for the applicable batch.
✓ Certificate of Analysis – Accessible through the product QR code where a completed batch-specific document has been published.
✓ Safety Data Sheet – Supplied to support appropriate laboratory handling, storage and regulatory compliance where available.
✓ Sequence documentation – The complete Gly-His-Lys tripeptide sequence should be confirmed using the applicable synthesis and batch records.
✓ Palmitoylation documentation – The covalent N-terminal palmitoyl modification should be supported by appropriate molecular-identity data.
✓ Terminal-structure documentation – The free C-terminal carboxylic acid structure should be confirmed using the applicable molecular-identity records.
✓ Mass-spectrometry documentation – Molecular identity should be supported by analytical mass data consistent with the specified PAL-GHK structure.
✓ Purity documentation – The reported chromatographic purity applies only to the analytical method and batch stated in the Certificate of Analysis.
✓ Lipopeptide-content documentation – Net PAL-GHK content should be distinguished from chromatographic purity and interpreted alongside water, counter-ion and residual-solvent results.
✓ Chemical-form documentation – The uncountered lipopeptide, trifluoroacetate form, acetate form or other counter-ion presentation should be identified clearly in the applicable product and batch records.
✓ Bacterial endotoxin documentation – The applicable bacterial endotoxin or lipopolysaccharide result should identify the test method, reporting units, method-suitability controls and acceptance criterion.
✓ Supplier documentation – Reviewed where supporting synthesis, palmitoylation, purification and analytical records are supplied.
✓ Fast, reliable and trackable express delivery – Securely packaged and dispatched using insulated or temperature-managed packaging where required by the applicable transport and storage specification.

For Research Use Only
This product is supplied strictly for scientific research, laboratory analysis and experimental work. It is not intended for human consumption, animal use, clinical use, diagnostic use or any form of therapeutic application.

PAL-GHK Product Overview

Our PAL-GHK research-grade palmitoylated tripeptide, also known as Palmitoyl Tripeptide-1, is supplied for controlled scientific laboratory investigation, analytical method development, lipopeptide characterisation, high-performance liquid chromatography assessment, mass-spectrometry workflows, formulation studies and reference-material comparison.

PAL-GHK comprises the defined Gly-His-Lys tripeptide sequence containing a covalently attached N-terminal palmitoyl group and a free C-terminal carboxylic acid. The lipid modification substantially changes the physicochemical properties of the underlying GHK tripeptide and should therefore be confirmed as part of the molecular-identity assessment.

The material is handled with a focus on batch traceability, documented quality control and consistent laboratory presentation. Product identity, amino-acid sequence, N-terminal palmitoylation, terminal structure, chromatographic purity, net lipopeptide content, molecular form, counter-ion content, water content, residual solvents, aggregation, bacterial endotoxin results and other analytical specifications should be confirmed using the applicable batch Certificate of Analysis.

The CAS number 147732-56-7, molecular formula C₃₀H₅₄N₆O₅ and average molecular weight of approximately 578.79 g/mol describe the uncountered PAL-GHK free-acid molecule. Where the supplied laboratory material contains trifluoroacetate, acetate, residual water, solvents or formulation ingredients, the applicable batch documentation should identify their contribution to the total supplied material mass.

PAL-GHK should not be confused with unmodified GHK or GHK-Cu. Unmodified GHK does not contain the palmitoyl group, while GHK-Cu is a copper coordination complex. PAL-GHK contains no copper unless a copper component is separately and expressly declared in the applicable product formulation and batch documentation.

Chromatographic purity should not automatically be interpreted as equivalent to total net PAL-GHK content. Likewise, a bacterial endotoxin or lipopolysaccharide result does not establish sterility, molecular identity, correct N-terminal palmitoylation, sequence integrity or the absence of every synthesis-related and process-related impurity.

For the majority of routine analytical, chromatographic, formulation, lipopeptide-characterisation and general laboratory work, the Regular PAL-GHK specification remains highly suitable. The premium black-and-gold ULTIMATE PAL-GHK option provides an additional preparative high-performance liquid chromatography purification stage and a more stringent bacterial endotoxin and lipopolysaccharide testing specification for scientific projects requiring enhanced quality-control parameters.

View Certificate of Analysis

View Safety Data Sheet